Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Premenopausal Women ◽

Randomised Trials ◽

Phase 3 ◽

Two Phase ◽

Combined Analysis ◽

Ovarian Suppression ◽

28194 Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.727 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB178

Author(s):

Eric L. Simpson ◽

Matthias Augustin ◽

Diamant Thaçi ◽

Laurent Misery ◽

Jonathan I. Silverberg ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Two Phase ◽

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Cancer ◽

10.1002/cncr.32873 ◽

2020 ◽

Vol 126 (13) ◽

pp. 3132-3139 ◽

Cited By ~ 3

Author(s):

PierFranco Conte ◽

Andreas Schneeweiss ◽

Sibylle Loibl ◽

Eleftherios P. Mamounas ◽

Gunter Minckwitz ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Invasive Disease ◽

Trastuzumab Emtansine ◽

Phase 3 ◽

Adjuvant Trastuzumab ◽

Patient Reported ◽

Epidermal Growth ◽

Positive Breast Cancer

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

Cancer ◽

10.1002/cncr.28465 ◽

2013 ◽

Vol 120 (5) ◽

pp. 642-651 ◽

Cited By ~ 68

Author(s):

Manfred Welslau ◽

Veronique Diéras ◽

Joo-Hyuk Sohn ◽

Sara A. Hurvitz ◽

Deepa Lalla ◽

...

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 3 ◽

Patient Reported ◽

Epidermal Growth

PCN91 ARTHRALGIA AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER TAKING AROMATASE INHIBITORS: LONGITUDINAL ANALYSES

Value in Health ◽

10.1016/j.jval.2011.02.946 ◽

2011 ◽

Vol 14 (3) ◽

pp. A171

Author(s):

L.D. Castel ◽

I.A. Mayer ◽

H. Chen ◽

S.E. McLellan ◽

S.A. Deppen ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Aromatase Inhibitors ◽

Longitudinal Analyses ◽

1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes

European Journal of Cancer ◽

10.1016/s0959-8049(16)30767-5 ◽

2015 ◽

Vol 51 ◽

pp. S270-S271 ◽

Cited By ~ 3

Author(s):

N. Harbeck ◽

M. Cristofanilli ◽

J. Ro ◽

F. André ◽

S. Loi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Patient Reported ◽

Post Menopausal

1817MO Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1464 ◽

2020 ◽

Vol 31 ◽

pp. S1049

Author(s):

P. Lapidari ◽

A. Gbenou ◽

J. Havas ◽

E. Martin ◽

B. Pistilli ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Hematologic Toxicity ◽

Colony Stimulating Factors ◽

Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review

Patient Related Outcome Measures ◽

10.2147/prom.s195296 ◽

2019 ◽

Vol Volume 10 ◽

pp. 117-127 ◽

Cited By ~ 2

Author(s):

Cathrine Lundgaard Riis ◽

Troels Bechmann ◽

Pernille Tine Jensen ◽

Angela Coulter ◽

Karina Dahl Steffensen

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Scoping Review ◽

Post Treatment ◽

Patient Reported ◽

Follow Up Care

Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials

Modern Rheumatology ◽

10.1080/14397595.2017.1422232 ◽

2018 ◽

Vol 28 (6) ◽

pp. 950-959 ◽

Cited By ~ 7

Author(s):

Naoki Ishiguro ◽

Maxime Dougados ◽

Zhihong Cai ◽

Baojin Zhu ◽

Masato Ishida ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trials ◽

Disease Activity ◽

Phase 3 ◽

Two Phase ◽

Patient Reported ◽

Post Hoc

PCN313 Adjuvant Chemotherapy Related SIDE Effects for Treatment of EARLY Breast Cancer Patients; A Literature Study and Comparison to Patient-Reported Outcomes Collected in the Netherlands

Value in Health ◽

10.1016/j.jval.2020.08.450 ◽

2020 ◽

Vol 23 ◽

pp. S478

Author(s):

D. Grobben ◽

P. Nieboer ◽

G.J. Liefers ◽

M. Bos ◽

L. Saes ◽

...

Keyword(s):

Breast Cancer ◽

Side Effects ◽

Adjuvant Chemotherapy ◽

The Netherlands ◽

Cancer Patients ◽

Early Breast Cancer ◽

Breast Cancer Patients ◽

Literature Study ◽

Faculty of 1000 evaluation for Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718174893.793487057 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Epidermal Growth Factor Receptor ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Phase 3 ◽

Patient Reported ◽

Epidermal Growth